Characterization of low-density lipoprotein cholesterol-lowering efficacy for atorvastatin in a population-based DNA biorepository

Russell A. Wilke, Richard L. Berg, James G. Linneman, Chengfeng Zhao, Catherine A. McCarty, Ronald M. Krauss

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

The Marshfield Clinic Personalized Medicine Research Project (PMRP) represents a large population-based biobank located in central Wisconsin. To position the PMRP database for large-scale pharmacogenetic association studies in the context of lipid-lowering therapy, we constructed an electronic phenotyping algorithm to quantify exposure and dose-response for atorvastatin, the most commonly prescribed lipid-lowering agent within this population. The resulting datasets were used to generate five distinct parameters for atorvastatin-induced changes in low-density lipoprotein (LDL) cholesterol level: (i) pretreatment, baseline LDL level [E0]; (ii) absolute reduction in LDL; (iii) relative reduction in LDL; (iv) potency [ED50]; and (v) maximal efficacy [Emax]. These parameters will facilitate the efficient application of electronic phenotyping for drug outcomes in the context of large pharmacogenetic association studies.

Original languageEnglish (US)
Pages (from-to)354-359
Number of pages6
JournalBasic and Clinical Pharmacology and Toxicology
Volume103
Issue number4
DOIs
StatePublished - Oct 2008

Fingerprint

Dive into the research topics of 'Characterization of low-density lipoprotein cholesterol-lowering efficacy for atorvastatin in a population-based DNA biorepository'. Together they form a unique fingerprint.

Cite this